​

Lipocine (LPCN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Lipocine Revenue Highlights

Latest Revenue (Y)

$109.99K

Latest Revenue (Q)

$89.56K

Main Segment (Y)

License

Lipocine Revenue by Period

Lipocine Revenue by Year

DateRevenueChange
2023-12-31$109.99K-78.00%
2022-12-31$500.00K-96.90%
2021-12-31$16.14M100.00%
2020-12-31--100.00%
2019-12-31$164.99K-61.45%
2018-12-31$428.03K100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31--

Lipocine generated $109.99K in revenue during NA 2023, up -78.00% compared to the previous quarter, and up 25.70% compared to the same period a year ago.

Lipocine Revenue by Quarter

DateRevenueChange
2024-06-30$89.56K-98.82%
2024-03-31$7.62M3423.40%
2023-12-31$216.19K-106.92%
2023-09-30$-3.12M100.00%
2023-06-30--100.00%
2023-03-31$54.99K100.00%
2022-12-31-100.00%
2022-09-30--100.00%
2022-06-30$500.00K100.00%
2022-03-31--100.00%
2021-12-31$16.09M29150.18%
2021-09-30$54.99K100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31--100.00%
2019-09-30$164.99K100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30--100.00%
2018-03-31$428.03K100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31--100.00%
2016-12-31$13.50M100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31--

Lipocine generated $89.56K in revenue during Q2 2024, up -98.82% compared to the previous quarter, and up 162.88% compared to the same period a year ago.

Lipocine Revenue Breakdown

Lipocine Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
License$109.99K$500.00K$11.00M
Materials--$1.04M
Minimum guaranteed royalties--$4.05M
Sales-based royalties--$54.99K

Lipocine's latest annual revenue breakdown by segment (product or service), as of Dec 23: License (100.00%).

Lipocine Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARDXArdelyx$124.46M$98.24M
UNCYUnicycive Therapeutics$675.00K-
LPCNLipocine$109.99K$89.56K
CKPTCheckpoint Therapeutics$103.00K-
EYENEyenovia$3.79K$1.63K
ZVSAZyVersa Therapeutics--
KODKodiak Sciences--
VSTMVerastem-$10.00M
RVPHReviva Pharmaceuticals--
ZURAZura Bio--
CGTXCognition Therapeutics--
HEPAHepion Pharmaceuticals--
RNAZTransCode Therapeutics--
MBIOMustang Bio--

LPCN Revenue FAQ

What is Lipocine’s yearly revenue?

Lipocine's yearly revenue for 2023 was $109.99K, representing a decrease of -78.00% compared to 2022. The company's yearly revenue for 2022 was $500K, representing a decrease of -96.90% compared to 2021. LPCN's yearly revenue for 2021 was $16.14M, representing an increase of 100.00% compared to 2020.

What is Lipocine’s quarterly revenue?

Lipocine's quarterly revenue for Q2 2024 was $89.56K, a -98.82% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $7.62M, a 3423.40% increase from the previous quarter (Q4 2023), and a 13751.93% increase year-over-year (Q1 2023). LPCN's quarterly revenue for Q4 2023 was $216.19K, a -106.92% decrease from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).

What is Lipocine’s revenue growth rate?

Lipocine's revenue growth rate for the last 3 years (2021-2023) was -99.32%, and for the last 5 years (2019-2023) was -33.34%.

What are Lipocine’s revenue streams?

Lipocine's revenue streams in c 23 are License

What is Lipocine’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Lipocine was License. This segment made a revenue of $109.99K, representing 100.00% of the company's total revenue.